By Michael Dabaie

 

Landos Biopharma Inc. said it had a successful outcome of an end-of-Phase 2 meeting with the U.S. Food and Drug Administration for omilancor, its lead candidate for mild-to-moderate active ulcerative colitis.

Landos said it and the FDA agreed on key elements necessary for regulatory approval, clearing a path for a Phase 3 program with omilancor.

The program will include two Phase 3 clinical trials and evaluate a single dose of omilancor, with primary objectives of clinical remission at weeks 12 and 52, the company said.

Landos said it is working to finalize the details of the Phase 3 protocols based on feedback and guidance from the FDA.

Ulcerative colitis is a chronic, autoimmune, inflammatory bowel disease that is estimated to affect more than 900,000 patients in the U.S. and over 1 million patients throughout the rest of the world, Landos said.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

June 14, 2021 07:43 ET (11:43 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Landos Biopharma (NASDAQ:LABP)
Historical Stock Chart
From Jun 2021 to Jul 2021 Click Here for more Landos Biopharma Charts.
Landos Biopharma (NASDAQ:LABP)
Historical Stock Chart
From Jul 2020 to Jul 2021 Click Here for more Landos Biopharma Charts.